September 29, 2020 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that it will participate in a panel at the MD Life Sciences Bio Innovation ...
September 23, 2020 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that it will be participating in Precision Medicine’s webinar on utilizing liquid biopsy to ...
ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. (ITI) announced today that it will participate at the World Vaccine Congress Washington being held virtually September 28-October 1, 2020. Andrew Eisen, MD, Ph.D., ...
Seoul Office Will Be Opening to Develop Immunomic Therapeutics Investigational Cell Therapy for Brain Cancer September 10, 2020 08:00 AM Eastern Daylight Time SEOUL--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held ...
ITI Announces Publication of Results from 3 ATTAC Studies of CMV-Specific Dendritic Cell Vaccines for the Treatment of GBM
Immunomic Therapeutics Announces Publication of Results from 3 ATTAC Studies of CMV-Specific Dendritic Cell Vaccines for the Treatment of GBM~25-35 % survival over 5 years from diagnosis in vaccinated GBM ...
ITI was chosen as one of DC Inno’s on Fire Winners for 2020 alongside Emergent Biosolutions, Novavax and Viela Bio. Check it out… https://www.americaninno.com/dc/50-on-fire/meet-dc-innos-2020-Inno-on-fire DC Inno is your source for ...
-Immunomic to invest in Replicate’s seed round; funding will enable Replicate to accelerate self-replicating RNA technology and grow operations- June 24, 2020 08:00 AM Eastern Daylight Time ROCKVILLE, Md. & ...
ITI Enters into License Agreement with Ichor to Use Electroporation (EP) Delivery Technology in Phase I Study of DNA Vaccine Therapy, ITI-1001
-First-in-Human Phase I study is anticipated to commence in 2021- June 16, 2020 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering ...
Immunomic Therapeutics Incorporated (ITI), located in Rockville, Maryland recently announced it had closed on $61.3M in financing, exceeding its initial fundraising projections by over $11M. The Korean investment group HLB Co., LTD led ...
-ITI Board adds significant oncology drug development and commercialization expertise to the Board- May 05, 2020 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”) a privately-held clinical-stage ...
-Proceeds to support acceleration of Phase II clinical trial for GBM, advancement of pipeline, including development of COVID-19 vaccine candidate and expansion of opportunities for its UNITE nucleic acid platform- ...
GOLDEN, Colo., April 14, 2020 /PRNewswire/ -- PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its Tropis® Needle-free injection system will be used to deliver a COVID-19 vaccine being ...